{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:15:34Z","timestamp":1781111734737,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.drugalcdep.2016.06.027","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T18:31:13Z","timestamp":1467397873000},"page":"254-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["National trends in alcohol pharmacotherapy: Findings from an Australian claims database"],"prefix":"10.1016","volume":"166","author":[{"given":"Kirsten C.","family":"Morley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Logge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallie-Anne","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Baillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0005","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0010","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s11606-013-2402-8","article-title":"Health literacy and antidepressant medication adherence among adults with diabetes: the diabetes study of Northern California (DISTANCE)","volume":"28","author":"Bauer","year":"2013","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0015","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1360-0443.2004.00763.x","article-title":"Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review","volume":"99","author":"Bouza","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0020","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","article-title":"Medication adherence: WHO cares?","volume":"86","author":"Brown","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/alcalc\/agm038","article-title":"Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland","volume":"42","author":"Buri","year":"2007","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0030","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.drugalcdep.2014.11.029","article-title":"Delay to first treatment contact for alcohol use disorder","volume":"147","author":"Chapman","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/alcalc\/35.2.176","article-title":"United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol","volume":"35","author":"Chick","year":"2000","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0040","doi-asserted-by":"crossref","unstructured":"Collins, D.J., Lapsley, H.M., 2008. The Costs Of Tobacco, Alcohol And Illicit Drug Abuse To Australian Society In 2004\/05, National Drug Strategy Monograph Series No. 64, http:\/\/www.health.gov.au\/pubhlth\/publicat\/document\/mono64.pdf.","DOI":"10.1037\/e674312010-001"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0045","doi-asserted-by":"crossref","first-page":"218","DOI":"10.5694\/j.1326-5377.2003.tb05506.x","article-title":"New pharmacotherapies for alcohol dependence: are they being used and what do they cost?","volume":"197","author":"Doran","year":"2003","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1300\/J069v23n04_02","article-title":"Naltrexone and pharmacy benefit management","volume":"23","author":"Harris","year":"2004","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0055","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/01.jcp.0000084029.22282.bb","article-title":"Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects","volume":"23","author":"Johnson","year":"2003","journal-title":"J. Cin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0060","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0065","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/alcalc\/agh093","article-title":"Combined therapy: what does acamprosate and naltrexone combination tell us?","volume":"39","author":"Kiefer","year":"2004","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0070","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","article-title":"Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study","volume":"60","author":"Kiefer","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1530-0277.1996.tb01036.x","article-title":"Elevated rates of early discontinuation from pharmacotherapy trials in alcoholics and drug abusers","volume":"20","author":"Kranzler","year":"1996","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0080","article-title":"The Range and Magnitude of Alcohol\u2019s Harm to Others","author":"Laslett","year":"2010"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0376-8716(03)00134-0","article-title":"Understanding US addiction physicians\u2019 low rate of naltrexone prescription","volume":"71","author":"Mark","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0090","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1360-0443.2003.00377.x","article-title":"Physicians\u2019 opinions about medications to treat alcoholism","volume":"98","author":"Mark","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0095","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/s13104-015-1616-8","article-title":"The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers","volume":"8","author":"Mellish","year":"2015","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0100","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/j.1360-0443.2006.01555.x","article-title":"Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial","volume":"101","author":"Morley","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0105","series-title":"Pharmacotherapies For Alcohol Dependence Guidelines For The Treatment of Alcohol Problems","first-page":"93","author":"Morley","year":"2009"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0110","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/alcalc\/agu062","article-title":"Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety","volume":"49","author":"Morley","year":"2014","journal-title":"Alcohol Alcohol."},{"issue":"4","key":"10.1016\/j.drugalcdep.2016.06.027_bib0115","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/alcalc\/agv131","article-title":"Is specialized integrated treatment for comorbid anxiety, depression and alcohol dependence better than treatment as usual in a public hospital setting?","volume":"51","author":"Morley","year":"2016","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0125","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1465-3362.2008.00019.x","article-title":"The association of alcohol dependence with general practice attendance","volume":"28","author":"Proudfoot","year":"2009","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0130","article-title":"Opioid antagonists for alcohol dependence","volume":"12","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0135","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0028-3908(01)00008-9","article-title":"The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801","volume":"40","author":"Rammes","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-244X-9-38","article-title":"Persistence and compliance to antidepressant treatment in patients with depression: a chart review","volume":"9","author":"Sawada","year":"2009","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0145","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archinte.164.7.722","article-title":"How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials","volume":"164","author":"Schroeder","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0150","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/j.1360-0443.2010.03096.x","article-title":"Prevalence and correlates of DSM-IV alcohol abuse and dependence in Australia: findings of the 2007 National Survey of Mental Health and Wellbeing","volume":"105","author":"Teesson","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0155","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.1997.01830200071010","article-title":"Naltrexone and alcohol dependence: role of subject compliance","volume":"54","author":"Volpicelli","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0160","series-title":"Global Information System on Alcohol and Health","author":"WHO","year":"2015"},{"key":"10.1016\/j.drugalcdep.2016.06.027_bib0165","doi-asserted-by":"crossref","first-page":"728","DOI":"10.18553\/jmcp.2009.15.9.728","article-title":"Comparing adherence and persistence across 6 chronic medication classes","volume":"15","author":"Yeaw","year":"2009","journal-title":"JMCP"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871616301740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871616301740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T06:53:35Z","timestamp":1615704815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871616301740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":33,"alternative-id":["S0376871616301740"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.06.027","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National trends in alcohol pharmacotherapy: Findings from an Australian claims database","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}